Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
about
HIV-1 integrase inhibitor resistance and its clinical implicationsCurrent perspectives on HIV-1 antiretroviral drug resistanceNovel therapeutic strategies targeting HIV integraseStructural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase InhibitorsNew Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of ActionBF integrase genes of HIV-1 circulating in São Paulo, Brazil, with a recurrent recombination regionStructural basis for HIV-1 DNA integration in the human genome, role of the LEDGF/P75 cofactorImpact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.The HIV-1 integrase α4-helix involved in LTR-DNA recognition is also a highly antigenic peptide elementHIV-1 IN inhibitors: 2010 update and perspectivesAntiretroviral therapy in the clinicRaltegravir: The evidence of its therapeutic value in HIV-1 infection.Resistance to integrase inhibitors.Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitnessPhysical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors.Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication.In vitro evolution of an HIV integrase binding protein from a library of C-terminal domain γS-crystallin variants.4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance ProfileElvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment.Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells.HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complexHIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.Influence of Drug Resistance Mutations on the Activity of HIV-1 Subtypes A and B Integrases: a Comparative Study.Novel 3'-Processing Integrase Activity Assay by Real-Time PCR for Screening and Identification of HIV-1 Integrase Inhibitors.Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors.Authentic HIV-1 integrase inhibitors.Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.Raltegravir: molecular basis of its mechanism of actionDiscovery of drugs that possess activity against feline leukemia virusStructural-Functional Analysis of 2,1,3-Benzoxadiazoles and Their N-oxides As HIV-1 Integrase Inhibitors.Binding mode prediction of biologically active compounds from plant Salvia Miltiorrhiza as integrase inhibitor.
P2860
Q24628743-7C27A762-2DAB-4C97-9628-91248E09863FQ26852626-6BCC0292-D838-41B5-BBF9-94C8305E3C77Q27003960-ED45FF54-97EB-4BCA-8053-BACBA271F938Q27670616-0B058853-22B2-48EC-9B2E-343677EE84B8Q27678141-E4824B4A-2ADD-47A6-904B-511C50DE86BFQ27678745-91D390D5-B4A2-4D30-B390-88782967411BQ28482075-320CD01A-8570-4D60-A4CC-A8E9893F096EQ30487128-AD08D79F-93AC-4BE9-82FB-710FF9FB43ABQ33559145-F72EF7FE-190C-4589-89CE-9C6A22B67ADBQ33786815-C4894A8E-5098-445A-8C60-5B566CA938CDQ33814351-0EF33E56-2316-4F86-B288-2BA047D79947Q33877347-62364630-E4C2-4D7A-AF14-CA75ECB641E2Q33973930-A870A813-A736-44BD-971E-BD2CEAD6EF06Q34059896-68E1CDCD-536E-4998-8107-1B79E2BB1D21Q34108775-ADAEDCDE-A2C1-4AE9-962D-AECD6E5F0C51Q34148077-FA49D4D5-AB83-4D13-ADBC-426262F2CBD5Q34245624-4EEAFE6B-9A1D-4406-8972-CE58AB9CA62AQ34350400-9BEBC187-3C9E-493D-8961-2AEC33E12A71Q34363222-E937A5FD-925C-47EF-B912-6A647B613354Q34435637-640774C9-C303-4449-BB40-7F7A27507AC5Q34520239-B9610121-96F9-4CBC-83F6-78FDDD46B6ECQ34540677-964BE2C5-6C8E-49B9-8F7B-0ADB1E7A9832Q34634156-267CC60D-91C2-43BF-8AB7-78D1EDD5E68FQ34737411-B817EC36-A5E1-4D72-8DBB-91EE2BCA0C03Q34993146-C682C86F-0F16-4206-9595-D68A82CC363CQ35068715-E4C9FB82-C5D3-4ED5-88D2-BA3E130B3E74Q35134947-07F42F36-71B6-4C48-BF2C-EC87CD274A7EQ35206272-02F2E858-702C-4F38-AF58-E755AB24C8A5Q35540399-E950D312-0B3C-43B1-8C1B-D8C62B84EF61Q35630516-B5599344-7DFC-4782-97B2-DF2490F75BC4Q35694729-1BB9D847-3C90-48BC-8F5D-781C0A6BC3E1Q35944477-610ABA94-CD0E-4AD7-A8EB-B78FC564E8B2Q36099861-B5518149-127A-4700-89C0-521D087E4B5DQ36145625-1C7CCDD1-633F-49FC-A393-A276FCEA3493Q36155580-499502C9-9D18-4C63-85E7-8D438CF3561BQ36284159-3CCCD568-0560-49BC-BF99-A2C84B1BF743Q36452171-37908E8C-A48E-4D1D-BA28-726181D5C000Q36525355-DD5EF3EB-1F71-4088-AF69-4A14C3B10FC8Q36730335-2C393BF0-1261-40CF-B312-0435FB57497DQ36894960-6A5B7BC7-FCA8-4100-90BD-4F8792CA8F38
P2860
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Mutations associated with fail ...... ity to the inhibitor in vitro.
@ast
Mutations associated with fail ...... ity to the inhibitor in vitro.
@en
type
label
Mutations associated with fail ...... ity to the inhibitor in vitro.
@ast
Mutations associated with fail ...... ity to the inhibitor in vitro.
@en
prefLabel
Mutations associated with fail ...... ity to the inhibitor in vitro.
@ast
Mutations associated with fail ...... ity to the inhibitor in vitro.
@en
P2093
P2860
P50
P356
P1476
Mutations associated with fail ...... ity to the inhibitor in vitro.
@en
P2093
Anne-Geneviève Marcelin
Brigitte Montes
Cathia Soulie
Isabelle Malet
Jacques Reynes
Jean-François Mouscadet
Luba Tchertanov
Marc Wirden
Marc-Antoine Valantin
Olivier Delelis
P2860
P304
P356
10.1128/AAC.01228-07
P407
P577
2008-01-28T00:00:00Z